STOCK TITAN

UNITED THERAPEUTICS (UTHR) CFO logs 10,000-share net sale via 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a combination of option exercise and share sales in company stock. He exercised stock options covering 10,000 shares of Common Stock at a strike price of $117.76 per share and, on the same date, executed open-market sales totaling 10,000 shares of Common Stock.

The sales were broken into multiple trades at weighted average prices generally in the mid‑$540 range per share, as detailed in the filing. According to the transaction summary, these moves result in a net disposition of 10,000 shares. The filing notes that the option exercise and subsequent share sales were carried out under a pre-arranged Rule 10b5-1 trading plan entered into by Edgemond on October 31, 2025.

Positive

  • None.

Negative

  • None.
Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.46M)
Type Security Shares Price Value
Exercise Stock Option 10,000 $0.00 --
Exercise Common Stock 10,000 $117.76 $1.18M
Sale Common Stock 120 $539.6393 $65K
Sale Common Stock 480 $541.1433 $260K
Sale Common Stock 440 $542.7769 $239K
Sale Common Stock 1,086 $544.1119 $591K
Sale Common Stock 1,545 $544.9442 $842K
Sale Common Stock 1,129 $545.8885 $616K
Sale Common Stock 1,033 $547.0035 $565K
Sale Common Stock 2,749 $548.0374 $1.51M
Sale Common Stock 1,298 $549.0586 $713K
Sale Common Stock 120 $550.4767 $66K
Holdings After Transaction: Stock Option — 30,000 shares (Direct, null); Common Stock — 28,876 shares (Direct, null)
Footnotes (1)
  1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $548.55 to $549.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $550.39 to $550.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $539.29 to $540.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $540.76 to $541.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $542.40 to $543.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $543.51 to $544.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $544.51 to $545.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $545.52 to $546.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $546.52 to $547.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $547.52 to $548.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 10,000 shares Open-market Common Stock sales on 2026-06-04
Option exercise shares 10,000 shares Stock options converted into Common Stock on 2026-06-04
Option strike price $117.76 per share Exercise price of stock options into Common Stock
Highest reported sale price $550.48 per share Weighted average sale price in one trade range
Lowest reported sale price $539.29 per share Low end of one disclosed trade price range
Net buy/sell shares 10,000 shares net sold transactionSummary netBuySellShares
Rule 10b5-1 trading plan financial
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026M(1)10,000A$117.7628,876D
Common Stock06/04/2026S(1)120D$539.6393(2)28,756D
Common Stock06/04/2026S(1)480D$541.1433(3)28,276D
Common Stock06/04/2026S(1)440D$542.7769(4)27,836D
Common Stock06/04/2026S(1)1,086D$544.1119(5)26,750D
Common Stock06/04/2026S(1)1,545D$544.9442(6)25,205D
Common Stock06/04/2026S(1)1,129D$545.8885(7)24,076D
Common Stock06/04/2026S(1)1,033D$547.0035(8)23,043D
Common Stock06/04/2026S(1)2,749D$548.0374(9)20,294D
Common Stock06/04/2026S(1)1,298D$549.0586(10)18,996D
Common Stock06/04/2026S(1)120D$550.4767(11)18,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$117.7606/04/2026M(1)10,00003/15/202303/15/2027Common Stock10,000$0.0030,000D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $539.29 to $540.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $540.76 to $541.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $542.40 to $543.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $543.51 to $544.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $544.51 to $545.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $545.52 to $546.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $546.52 to $547.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $547.52 to $548.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $548.55 to $549.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $550.39 to $550.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) CFO James Edgemond report?

CFO James Edgemond reported exercising options for 10,000 UNITED THERAPEUTICS shares and selling 10,000 shares in open-market trades. The activity reflects a net disposition of 10,000 shares, combining an option exercise with same‑day sales.

At what prices did the UNITED THERAPEUTICS (UTHR) CFO sell shares?

The CFO’s UNITED THERAPEUTICS share sales were executed in multiple trades at weighted average prices generally in the mid-$540 range per share. Individual trades occurred within specified intraday price ranges disclosed in the footnotes.

What stock options did the UNITED THERAPEUTICS (UTHR) CFO exercise?

He exercised stock options covering 10,000 UNITED THERAPEUTICS Common Stock shares with a strike price of $117.76 per share. This converted derivative holdings into common shares as part of the reported transactions.

Was the UNITED THERAPEUTICS (UTHR) CFO’s stock sale under a Rule 10b5-1 plan?

Yes. The filing states the option exercise and subsequent UNITED THERAPEUTICS share sales were executed pursuant to a Rule 10b5-1 trading plan entered into by the CFO on October 31, 2025, indicating a pre‑scheduled arrangement.

How many UNITED THERAPEUTICS (UTHR) shares did the CFO sell in total?

Across multiple open-market trades, the CFO sold a total of 10,000 UNITED THERAPEUTICS Common Stock shares. These sales, combined with the option exercise, produced a net disposition of 10,000 shares according to the transaction summary.

What does the transaction summary show for UNITED THERAPEUTICS (UTHR) CFO James Edgemond?

The transaction summary shows 10 sale transactions totaling 10,000 shares and one derivative exercise for 10,000 shares. Overall, it records a net-sell direction with netBuySellShares of 10,000 shares disposed.